Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Book
| BMRN - Biomarin Pharmaceutical | 12.82% | Hold | 1,831,035 | $86.68 | $159M | — | — |
| UTHR - United Therapeutics | 11.19% | Hold | 627,514 | $220.75 | $139M | — | — |
| Revance Therapeutics | 10.69% | Reduce −0.8% | 5,228,609 | $25.31 | $132M | −41,600 | −$37M |
| FOLD - Amicus | 10.68% | Hold | 10,524,022 | $12.56 | $132M | — | — |
| INSM - Insmed | 10.04% | Hold | 5,889,491 | $21.10 | $124M | — | — |
| PRTA - Prothena | 9.14% | Reduce −0.4% | 1,657,458 | $68.28 | $113M | −6,319 | +$33M |
| BIIB - Biogen | 8.77% | Hold | 381,282 | $284.85 | $109M | — | — |
| Staar Surgical | 5.84% | Add +2.0% | 1,374,822 | $52.57 | $72M | +27,500 | −$14M |
| ACAD - Acadia Pharmaceuticals | 4.65% | Hold | 2,405,793 | $23.95 | $58M | — | — |
| Sage Therapeutics | 3.27% | Hold | 859,517 | $47.02 | $40M | — | — |
| ALGN - Align Technology | 2.13% | Hold | 74,605 | $353.64 | $26M | — | — |
| NVCR - Novocure | 1.94% | Add +1663.1% | 578,118 | $41.50 | $24M | +545,328 | +$22M |
| EHTH - Ehealth | 1.78% | Add +1.9% | 2,739,379 | $8.04 | $22M | +50,000 | −$3M |
| ALKS - Alkermes | 1.53% | Hold | 603,400 | $31.30 | $19M | — | — |
| SNDX - Syndax Pharmaceuticals | 1.04% | Hold | 612,600 | $20.93 | $13M | — | — |
| Sarepta Therapeutics | 0.87% | New | 94,030 | $114.52 | $11M | +94,030 | +$11M |
| Karyopharm Therapeutics | 0.82% | Hold | 5,675,876 | $1.79 | $10M | — | — |
| ANAB - Anaptysbio | 0.71% | Hold | 431,224 | $20.34 | $9M | — | — |
| Nevro | 0.38% | New | 186,259 | $25.42 | $5M | +186,259 | +$5M |
| Gossamer Bio | 0.34% | Hold | 3,465,152 | $1.20 | $4M | — | — |
| CYTK - Cytokinetics | 0.29% | Hold | 111,717 | $32.62 | $4M | — | — |
| TVTX - Travere Therapeutics | 0.21% | Hold | 166,069 | $15.36 | $3M | — | — |
| VNDA - Vanda Pharmaceuticals | 0.17% | Reduce −32.9% | 324,073 | $6.59 | $2M | −158,624 | −$1M |
| RLMD - Relmada Therapeutics | 0.15% | Add +35.1% | 732,400 | $2.46 | $2M | +190,300 | +$577K |
| MIRM - Mirum Pharmaceuticals | 0.14% | Hold | 64,700 | $25.87 | $2M | — | — |
| Kezar Life Sciences | 0.13% | Hold | 656,200 | $2.45 | $2M | — | — |
| ALDX - Aldeyra Therapeutics | 0.11% | Hold | 160,800 | $8.39 | $1M | — | — |
| Gritstone Oncology | 0.10% | Hold | 666,127 | $1.95 | $1M | — | — |
| Holding | 0.05% | Hold | 27,100 | $24.93 | $676K | — | — |
| URGN - Urogen Pharma | 0.02% | Hold | 24,500 | $10.35 | $254K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2023 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Provention Bio | 0.78% | Exit | 0 | $24.10 | $9M | −390,800 | −$9M |
| Peak Bio | 0.03% | Exit | 0 | $0.6311 | $314K | −497,528 | −$314K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2